CA2785612C - Ev576 for use in the treatment of viral infections of the respiratory tract - Google Patents

Ev576 for use in the treatment of viral infections of the respiratory tract Download PDF

Info

Publication number
CA2785612C
CA2785612C CA2785612A CA2785612A CA2785612C CA 2785612 C CA2785612 C CA 2785612C CA 2785612 A CA2785612 A CA 2785612A CA 2785612 A CA2785612 A CA 2785612A CA 2785612 C CA2785612 C CA 2785612C
Authority
CA
Canada
Prior art keywords
agent
protein
acid sequence
amino acid
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2785612A
Other languages
English (en)
French (fr)
Other versions
CA2785612A1 (en
Inventor
Wynne Weston-Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volution Immuno Pharmaceuticals SA
Original Assignee
Volution Immuno Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1000318.4A external-priority patent/GB201000318D0/en
Priority claimed from GBGB1005071.4A external-priority patent/GB201005071D0/en
Application filed by Volution Immuno Pharmaceuticals SA filed Critical Volution Immuno Pharmaceuticals SA
Publication of CA2785612A1 publication Critical patent/CA2785612A1/en
Application granted granted Critical
Publication of CA2785612C publication Critical patent/CA2785612C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CA2785612A 2010-01-08 2011-01-10 Ev576 for use in the treatment of viral infections of the respiratory tract Active CA2785612C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1000318.4A GB201000318D0 (en) 2010-01-08 2010-01-08 Method of treatment
GB1000318.4 2010-01-08
GBGB1005071.4A GB201005071D0 (en) 2010-03-25 2010-03-25 Method of treatment
GB1005071.4 2010-03-25
PCT/GB2011/000022 WO2011083317A1 (en) 2010-01-08 2011-01-10 Ev576 for use in the treatment of viral infections of the respiratory tract

Publications (2)

Publication Number Publication Date
CA2785612A1 CA2785612A1 (en) 2011-07-14
CA2785612C true CA2785612C (en) 2019-09-10

Family

ID=44305222

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2785612A Active CA2785612C (en) 2010-01-08 2011-01-10 Ev576 for use in the treatment of viral infections of the respiratory tract

Country Status (9)

Country Link
US (4) US20120283167A1 (enExample)
EP (1) EP2521562B1 (enExample)
JP (1) JP5840623B2 (enExample)
CN (1) CN102762223B (enExample)
AU (2) AU2011204483B2 (enExample)
CA (1) CA2785612C (enExample)
NZ (1) NZ601018A (enExample)
PL (1) PL2521562T3 (enExample)
WO (1) WO2011083317A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201691481A1 (ru) * 2014-03-20 2017-02-28 Инфларкс Гмбх ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201602802D0 (en) 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
IL263481B2 (en) 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
JP7209637B2 (ja) 2017-04-21 2023-01-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン
AU2018383751B2 (en) 2017-12-13 2025-05-08 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
JP7629394B2 (ja) * 2018-09-10 2025-02-13 ヴォリューション イミュノ ファーマシューティカルズ エスエイ リウマチ性疾患の治療に使用するためのコバーシン
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
WO2020247610A1 (en) 2019-06-06 2020-12-10 Spiritus Therapeutics, Inc. Mesenchymal stem cell-derived extracellular vesicles and uses thereof for treating and diagnosing fibrotic diseases
US12097222B2 (en) 2019-06-06 2024-09-24 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
WO2020247675A1 (en) * 2019-06-06 2020-12-10 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
JP2023503776A (ja) 2019-09-27 2023-02-01 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115884764A (zh) * 2020-04-01 2023-03-31 硫创治疗公司 用于治疗乙型冠状病毒感染的半胱胺前体化合物
WO2021226404A1 (en) * 2020-05-08 2021-11-11 Kodiak Sciences Inc. Use of il-6 antibodies and vegf traps, and fusion constructs and conjugates thereof
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3734093A (en) 1992-02-27 1993-09-13 Merck & Co., Inc. Protein for inhibiting collagen-stimulated platelet aggregation
US7884066B2 (en) 1999-10-05 2011-02-08 The Regents Of The University Of California NELL-1 enhanced bone mineralization
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7884188B2 (en) 2003-06-02 2011-02-08 Varleigh Immuno Pharmaceuticals (Vip) Ltd Complement inhibitors
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
WO2007117241A1 (en) * 2006-04-12 2007-10-18 Biocryst Pharmaceuticals, Inc. Intramuscular antiviral treatments
US7274999B1 (en) * 2006-03-10 2007-09-25 Atmel Corporation Brownout detector system and method
EP2061501B1 (en) * 2006-09-08 2015-04-08 Volution Immuno Pharmaceuticals SA Method of treating respiratory disorders
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment

Also Published As

Publication number Publication date
CN102762223B (zh) 2014-09-03
JP2013516450A (ja) 2013-05-13
US20200155646A1 (en) 2020-05-21
US20170065677A1 (en) 2017-03-09
CN102762223A (zh) 2012-10-31
US9522171B2 (en) 2016-12-20
JP5840623B2 (ja) 2016-01-06
AU2011204483B2 (en) 2016-02-11
PL2521562T3 (pl) 2020-04-30
WO2011083317A1 (en) 2011-07-14
CA2785612A1 (en) 2011-07-14
AU2016203058B2 (en) 2018-01-18
EP2521562A1 (en) 2012-11-14
AU2011204483A1 (en) 2012-07-12
NZ601018A (en) 2013-09-27
US20120283167A1 (en) 2012-11-08
EP2521562B1 (en) 2019-09-18
AU2016203058A1 (en) 2016-06-02
US20150196619A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
AU2011204483B2 (en) EV576 for use in the treatment of viral infections of the respiratory tract
US20210244792A1 (en) Method of Treating Respiratory Disorders
US20200282018A1 (en) Method of Treating Myasthenia Gravis
AU2007293239B2 (en) Method of treating peripheral nerve disorders
DK2061501T3 (en) METHOD OF TREATING RESPIRATORY DISORDERS

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160104

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241204

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241204

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226